Navigation Links
'Forrest Gump' mice show too much of a good thing, can be bad
Date:6/20/2013

A line of genetically modified mice that Western University scientists call "Forrest Gump" because, like the movie character, they can run far but they aren't smart, is furthering the understanding of a key neurotransmitter called acetylcholine (ACh). Marco Prado and his team at Robarts Research Institute say the mice show what happens when too much of this neurotransmitter becomes available in the brain. Boosting ACh is a therapeutic target for Alzheimer's disease because it's found in reduced amounts when there's cognitive failure. Prado's research is published in the Journal of Neuroscience.

"We wanted to know what happens if you have more of the gene which controls how much acetylcholine is secreted by neurons," says Prado, a Robarts scientist and professor in the Departments of Physiology and Pharmacology and Anatomy and Cell Biology at Western's Schulich School of Medicine & Dentistry. "The response was the complete opposite of what we expected. It's not a good thing. Acetylcholine release was increased threefold in these mice, which seemed to disturb cognitive function. But put them on a treadmill and they can run twice as far as normal mice before tiring. They're super-athletes." In addition to its function in modulating cognitive abilities, ACh drives muscle contraction which allowed for the marked improvement in motor endurance.

One of the tests the scientists, including first author Benjamin Kolisnyk, used is called the touch screen test for mice which uses technology similar to a tablet. After initiating the test, the mice have to scan five different spots on the touch screen to see a light flash, and then run and touch that area. If they get it right they get a reward. Compared to the control mice, the "Forrest Gump" mice failed miserably at the task. The researchers found the mice, which have the scientific name ChAT-ChR2-EYFP, had terrible attention spans, as well as dysfunction in working memory and spatial memory.

Prado interprets the research as showing ACh is very important for differentiating cues. So if your brain is presented with a lot of simultaneous information, it helps to pick what's important. But when you flood the brain with ACh, your brain loses the ability to discern what's relevant. This study was funded mainly by the Canadian Institutes of Health Research.


'/>"/>

Contact: Kathy Wallis
kwallis3@uwo.ca
519-661-2111 x81136
University of Western Ontario
Source:Eurekalert

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market ... for Biometrics and Digital Identity".  Acuity characterizes 2017 ... identity when increased adoption reflects a new understanding ... "Biometrics and digital identity are often ... Maxine Most , Principal of Acuity Market ...
(Date:1/21/2017)... 20, 2017 Research and Markets has announced ... report to their offering. ... The global voice recognition biometrics market to grow ... The report covers the present scenario and the growth prospects ... the market size, the report considers the revenue generated from the ...
(Date:1/13/2017)... WASHINGTON, N.Y. , Jan. 13, 2017 /PRNewswire/ ... of technology solutions for the homecare industry, including ... of homecare industry expert, Justin Jugs, as Senior ... brings more than 15 years of homecare experience ... team in developing strategic plans to align Sandata,s ...
Breaking Biology News(10 mins):
(Date:2/20/2017)... -- Atrius Health and IBM (NYSE: IBM ) ... develop a cloud based service designed to improve ... of the multiple influences on an individual,s health, ... designed to support shared decision making between physicians ... healthcare organization with 875 physicians caring for 675,000 ...
(Date:2/18/2017)... Research and Markets has announced the addition of the ... ... provides separate comprehensive analytics for the US, Japan ... estimates and forecasts are provided for the period 2015 through 2022. ... data and analytics are derived from primary and secondary research. This ...
(Date:2/17/2017)... MILPITAS, Calif. , Feb. 17, 2017 /PRNewswire/ ... posters detailing data on its oral peptide drug ... Congress of the European Crohn,s and Colitis ... in Barcelona, Spain from ... The posters detail preclinical data on Protagonist drug ...
(Date:2/16/2017)... , Feb. 16, 2017  MDNA Life ... the development of liquid biopsy tests based on ... into an exclusive license agreement with its first ... proprietary liquid biopsy test for prostate cancer, the ... Korea . This is the first overseas ...
Breaking Biology Technology: